Precision Microbiota Interventions for Senoreduction Trial

Part of paid clinical trials in New Orleans, Louisiana.

Sponsor
Louisiana State University Health Sciences Center in New Orleans
Study ID
NCT07462767
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Limosilactobacillus reuteri — DIETARY_SUPPLEMENT
    Administered as 6 capsules daily (3 twice daily) for 4 weeks. Each daily dose contains 1×10\^10 CFU total in a 1:1 ratio of two strains. This is a GRAS dietary supplement and not an FDA-regulated investigational product.
  • Blueberry extract — DIETARY_SUPPLEMENT
    Administered as 6 capsules daily (3 twice daily) for 4 weeks, providing 500 mg anthocyanins per day. This is a GRAS dietary supplement and not an FDA-regulated investigational product.

Study Details

People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.

Key Dates

Start date
Apr 1, 2026
Status verified
Mar 2026
Primary completion
Dec 1, 2029
Completion
Dec 1, 2029

Study Design

Enrollment
160 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Sequence A: Probiotic then Blueberry Extract
    Participants receive probiotic for 4 weeks, washout 6 weeks, then blueberry extract for 4 weeks.
  • Experimental: Sequence B: Blueberry Extract then Probiotic
    Participants receive blueberry extract for 4 weeks, washout 6 weeks, then probiotic for 4 weeks.

Primary Outcome Measure

Change in circulating senescent T cell numbers [ Time Frame: Time 0 to Week 4 of treatment period ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
LSU HealthNew OrleansLouisiana70112
David A Welsh, MD
[email protected]
United States

Find similar trials in New Orleans, LA

By condition
HIV
By specialty
Infectious disease
By research site
LSU Health· New Orleans, LA

Related Studies